Handelsinvest Investeringsforvaltning Invests $755,000 in Evolent Health Inc (EVH)
Handelsinvest Investeringsforvaltning bought a new stake in Evolent Health Inc (NYSE:EVH) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 60,000 shares of the technology company’s stock, valued at approximately $755,000.
Several other institutional investors and hedge funds have also modified their holdings of EVH. Parkside Financial Bank & Trust increased its holdings in shares of Evolent Health by 57.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,628 shares of the technology company’s stock valued at $72,000 after purchasing an additional 1,327 shares during the period. We Are One Seven LLC acquired a new position in shares of Evolent Health in the 4th quarter valued at about $99,000. Jane Street Group LLC acquired a new position in shares of Evolent Health in the 3rd quarter valued at about $205,000. Amalgamated Bank acquired a new position in shares of Evolent Health in the 3rd quarter valued at about $225,000. Finally, Equitable Trust Co. acquired a new position in shares of Evolent Health in the 3rd quarter valued at about $227,000.
A number of equities analysts have recently weighed in on EVH shares. Zacks Investment Research downgraded Evolent Health from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. KeyCorp lowered their price target on Evolent Health from $32.00 to $20.00 and set an “overweight” rating for the company in a research note on Monday, March 4th. Cantor Fitzgerald reissued a “buy” rating and issued a $37.00 price target on shares of Evolent Health in a research note on Monday, December 31st. Finally, TheStreet cut Evolent Health from a “c-” rating to a “d+” rating in a research note on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $26.54.
Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Tuesday, February 26th. The technology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02). The firm had revenue of $193.10 million during the quarter, compared to the consensus estimate of $188.66 million. Evolent Health had a negative net margin of 8.40% and a negative return on equity of 2.39%. The company’s quarterly revenue was up 69.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.04) EPS. On average, analysts predict that Evolent Health Inc will post -0.81 EPS for the current year.
WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/handelsinvest-investeringsforvaltning-invests-755000-in-evolent-health-inc-evh/2955248.html.
Evolent Health Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Article: What is Depreciation?
Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health Inc (NYSE:EVH).
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.